banner add

Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.

from NYT > Health https://ift.tt/NWShtOr
via IFTTT

No comments

Frank Hayden, Who Led Global Growth of the Special Olympics, Dies at 96

His research showing the positive effects of athletics on intellectually disabled children led Eunice Kennedy Shriver to ask him to help sta...

Theme images by PLAINVIEW. Powered by Blogger.